11 Fastest Growing Penny Stocks to Buy Right Now

Page 7 of 10

4. Compugen Ltd. (NASDAQ:CGEN)

On March 2, 2026, Compugen Ltd. (NASDAQ:CGEN) reported fourth-quarter revenue of $67.3 million compared with $1.5 million in the prior year. Chief Executive Officer Eran Ophir said the company made important progress in 2025, citing the extension of its cash runway into 2029 through a non-dilutive monetization agreement with AstraZeneca for rilvegostomig. Ophir noted the agreement strengthens the company’s cash position while maintaining exposure to the potential long-term value of the asset, which AstraZeneca is advancing across 10 Phase 3 clinical trials in lung, gastrointestinal, and endometrial cancers, with additional Phase 1/2 data expected in 2026.

On February 12, 2026, Compugen Ltd. (NASDAQ:CGEN) announced the appointment of healthcare strategist Michele Holcomb as an independent director on its board. Holcomb brings more than 30 years of experience across biotechnology, pharmaceuticals, and healthcare services, including leadership roles at Cardinal Health, Teva, and McKinsey. The company said Holcomb’s background in strategy, business development, and partnerships is expected to support the use of its AI-driven discovery engine, pipeline development, and collaborations.

Compugen Ltd. (NASDAQ:CGEN) is a clinical-stage therapeutic discovery and development company focused on developing therapeutics and product candidates in Israel, the United States, and Europe.

Page 7 of 10